Table I.
Clinical information of 14 patients with pulmonary LELC.
| Case no./sex/age, years | Smoking history | Tumor location | Size, cm | Stage (TNM) | EBER | Treatment | Outcome (Alive/Deceased/Could not be contacted since diagnosis) |
|---|---|---|---|---|---|---|---|
| 1/M/38 | Yes | RUL | 3.5×3.4 | IIIB (T2a N3 M0) | + | No treatment | Alive, 20 months |
| 2/M/56 | Yes | LUL | 1.6×1.2 | IIIA (T2 N2 M0) | ND | SG + ChT (TP ×5) | Alive, 60 months |
| 3/F/61 | No | RUL | 6.3×6.1 | IIIB (T4 N2 M0) | ND | SG | Alive, 54 months |
| 4/M/55 | No | LLL | 5.9×3.6 | IIB (T2b N1 M0) | ND | SG + ChT (TP ×4) | Alive, 58 months |
| 5/F/52 | No | RLL | 6.5×5.0 | IV (T2 N1 M1a) | + | Biopsy + ChT (TP ×4) | Alive, 17 months |
| 6/F/22 | No | RML | 2.1×2.0 | IIIB (T2 N3 M0) | + | SG + ChT (NP ×4) + RT | Alive, 22 months |
| 7/M/61 | No | LUL | 2.0×2.0 | IIIA (T1a N2 M0) | + | SG + ChT (PP ×5) | Alive, 25 months |
| 8/M/57 | Yes | RLL | 4.6×4.0 | IV (T2a N3 M1) | + | No treatment | Deceased, 14 months |
| 9/M/61 | No | RML | 3.5×3.0 | IB (T2a N0 M0) | + | SG + ChT (DP ×4) | Alive, 39 months |
| 10/F/64 | No | LLL | 2.3×1.9 | IA (T1 N0 M0) | + | SG | Alive, 38 months |
| 11/M/46 | Yes | RML | 3.5×3.0 | IB (T2a N0 M0) | + | SG + ChT (DP ×4) | Alive, 31 months |
| 12/F/42 | No | RUL | 6.0×5.1 | IIIA (T4 N0 M0) | ND | SG + ChT (NP ×1+ GP ×3) | Alive, 12 months |
| 13/F/54 | No | LLL | 3.4×2.7 | IIIA (T2a N2 M0) | ND | SG + ChT (GP ×4) | Alive, 31 months |
| 14/F/48 | No | LLL | 3.6×2.7 | IV (T2 N2 M1a) | + | SG + ChT (TP ×4) | Could not be contacted |
TNM, tumor-node-metastasis; F, female; M, male; RUL, right upper lobe of lung; LUL, left upper lobe of lung; LLL, left lower lobe of lung; RLL, right lower lobe of lung; RML, right middle lobe of lung; +, positive; ND, not done; SG, surgery; ChT, chemotherapy; RT, radiotherapy; EBER, Epstein-Barr virus-encoded RNA; TP, paclitaxel + cisplatin/carboplatin; NP, navelbine + cisplatin/carboplatin; DP, docetaxel + cisplatin/carboplatin; PP, pemetrexed + cisplatin/carboplatin; GP, gemcitabine + cisplatin/carboplatin; LELC, lymphoepithelioma-like carcinoma.